<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND AND OBJECTIVE: The presence of <z:hpo ids='HP_0001655'>patent foramen ovale</z:hpo> (<z:mp ids='MP_0004225'>PFO</z:mp>) and atrioseptal <z:hpo ids='HP_0002617'>aneurysm</z:hpo> (<z:chebi fb="37" ids="15365">ASA</z:chebi>)has been described as a risk factor in cryptogenetic <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Patients with unknown origin <z:hpo ids='HP_0001297'>stroke</z:hpo> and <z:mp ids='MP_0004225'>PFO</z:mp> have less severe symptoms compared to the rest of cryptogenetic <z:hpo ids='HP_0001297'>stroke</z:hpo> patients </plain></SENT>
<SENT sid="2" pm="."><plain>We evaluated the clinical situation in <z:hpo ids='HP_0001297'>stroke</z:hpo> patients with <z:mp ids='MP_0004225'>PFO</z:mp> and describe the factors predictive of a better outcome after a year </plain></SENT>
<SENT sid="3" pm="."><plain>PATIENTS AND METHOD: 1118 patients between 18 and 70 years old were evaluated, and 223 were classified as having cryptogenetic <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>Our protocol Included transcranial Doppler, a transesophageal echocardiography (TEE) and a cranial RM </plain></SENT>
<SENT sid="5" pm="."><plain>We used the NIH <z:hpo ids='HP_0001297'>Stroke</z:hpo> Scale (NIHSS) to evaluate the clinical situation, and the modified Ranking Scale for the functional outcome </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: A total of 117 patients had <z:hpo ids='HP_0000001'>all</z:hpo> inclusion criteria </plain></SENT>
<SENT sid="7" pm="."><plain>66 (56.4%) showed a <z:mp ids='MP_0004225'>PFO</z:mp> </plain></SENT>
<SENT sid="8" pm="."><plain>We observed a younger age, a higher percentage of females (48.4% in <z:mp ids='MP_0004225'>PFO</z:mp> vs. 25.5% in no-<z:mp ids='MP_0004225'>PFO</z:mp>) and less risk factors in <z:mp ids='MP_0004225'>PFO</z:mp> patients, except for <z:hpo ids='HP_0002076'>migraine</z:hpo> (24.6% in <z:mp ids='MP_0004225'>PFO</z:mp> vs. 5.9% in no-<z:mp ids='MP_0004225'>PFO</z:mp>; p = 0.01) </plain></SENT>
<SENT sid="9" pm="."><plain><z:mp ids='MP_0004225'>PFO</z:mp> patients had less severe <z:hpo ids='HP_0001297'>strokes</z:hpo> (NIHSS: 3--median--in <z:mp ids='MP_0004225'>PFO</z:mp> vs. 5 in no-<z:mp ids='MP_0004225'>PFO</z:mp>; p = 0.010) and a lower grade of sequelae (p 0.024) </plain></SENT>
<SENT sid="10" pm="."><plain>Worse outcome was related to male, initial neurological evaluation (NIHSS) and presence of <z:chebi fb="37" ids="15365">ASA</z:chebi> </plain></SENT>
<SENT sid="11" pm="."><plain>After a logistic regression, only the initial clinical situation (NIHSS) and the presence of <z:chebi fb="37" ids="15365">ASA</z:chebi> were associated with sequelae </plain></SENT>
<SENT sid="12" pm="."><plain>CONCLUSIONS: <z:mp ids='MP_0004225'>PFO</z:mp> patients showed a less severe <z:hpo ids='HP_0001297'>stroke</z:hpo> and better functional outcome </plain></SENT>
<SENT sid="13" pm="."><plain>The initial neurological involvement and the presence of <z:chebi fb="37" ids="15365">ASA</z:chebi> are predictive of the clinical situation after a year </plain></SENT>
</text></document>